Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...

Full description

Saved in:
Bibliographic Details
Main Authors: Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N. Rich, Julie A. Norfleet, Sridharan Gururangan, Henry S. Friedman, David A. Reardon
Other Authors: Duke University School of Medicine
Format: Article
Published: 2018
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/28591
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/28591

Similar Items